Baili Zhang

Also affiliated with Southeast University

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting”.

Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2403

N/A

1.5DataRank · unranked

34 citations

Rajyalakshmi Luthra, Yusha Liu, Dzifa Y. Duose, Wonyul Lee, Neelima G. Reddy +20 more

Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers

UNC Libraries(2020)10.17615/zfd3-9433

N/A

0DataRank · unranked

11 citations

D. Neil Hayes, Wenli Dong, Menghong Sun, Kristy L. Richards, Charmaine D. Wilson +7 more

Consensus molecular subtypes (CMS) as a marker for treatment and disease biology in metastatic colorectal cancer (CRC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.4089

N/A

0DataRank · unranked

2 citations

Preeti Kanikarla Marie, Amir Mehrvarz Sarshekeh, Van K. Morris, Dzifa Y. Duose, Baili Zhang +6 more

Myotonic dystrophy type 1 (DM1) clinical subtypes and CTCF site methylation status flanking the CTG expansion are mutant allele length-dependent

Human Molecular Genetics(2021)10.1093/hmg/ddab243

N/A

0DataRank · unranked

22 citations

Eyleen Corrales, Baili Zhang, Melissa Vásquez, Carolina Santamaría‐Ulloa, Hazel Quesada +5 more

Multiomics profiling and association with molecular and immune features in association with benefits from immunotherapy for patients with previously treated stage IV or recurrent squamous cell lung cancer from the phase III SWOG LungMAP S1400I trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9046

N/A

0DataRank · unranked

0 citations

Dzifa Y. Duose, Jiexin Zhang, Mary W. Redman, Rossana Lazcano Segura, Mario L. Marques‐Piubelli +14 more